iBio, Inc. (IBIO) Key Metrics
IBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $49.3M
- Enterprise value
- −$6.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 492.8
- Price / book
- 0.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.26
IBIO key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsIBIO returns How much profit the business earns on the capital it uses.
Return on equity+35.8 pts
−65.7%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets+16.8 pts
−54.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover−89.4%
0.00
FY2026 · hover or tap a bar for each year
FY2017FY2026
IBIO financial health Debt, liquidity and how easily interest is covered.
Debt / equity−89.1%
0.03
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt−$80.8M
−$85.8M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio+393.2%
7.85
FY2026 · hover or tap a bar for each year
FY2017FY2026
Interest coverage
-663.0
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets−85.3%
0.02
FY2026 · hover or tap a bar for each year
FY2017FY2026
IBIO efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+1,833 days
2,206 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding
1,171 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle
1,035 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue+574.0 pts
578.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
IBIO valuation history
Fiscal year-endToday10-year median
IBIO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IBIO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IBIO cash returned to shareholders
DividendsBuybacksFree cash flow
IBIO price vs earnings per share
Share price at year-endEPS (right axis)
IBIO key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $182.1M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $96.3M | — | — | — | — | — | — | — | — | — |
| Price / book | 2.1 | — | — | — | — | — | — | — | — | — |
| EV / sales | 962.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −18.1% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −13.1% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.75 | $0.76 | $2.11 | $12.20 | $130.00 | $755.00 | $1,110.00 | $355.00 | $450.00 | $1,950.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.32 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.22 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.23 | — | — | — | — | — | — | — | — | — |
| Cash per share | $0.85 | — | — | — | — | — | — | — | — | — |
| Book value per share | $0.82 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.81 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.02 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 104.1M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −65.7% | −101.5% | −135.7% | −74.3% | −58.6% | −28.1% | −55.6% | −188.9% | −128.4% | −154.2% |
| Return on invested capital (ROIC) | — | −137.5% | −71.6% | −57.3% | −46.9% | −62.4% | −38.6% | −51.7% | −43.7% | −58.7% |
| Return on assets (ROA) | −54.0% | −70.8% | −71.2% | −41.7% | −40.9% | −19.2% | −26.3% | −47.8% | −40.7% | −33.2% |
| Return on tangible assets | −34.0% | −112.5% | −106.6% | −81.8% | −53.3% | −15.9% | −17.7% | −60.2% | −38.8% | −42.5% |
| Free cash flow margin | — | — | — | — | — | — | −885.2% | −741.6% | — | — |
| Financial health | ||||||||||
| Total debt | $2.2M | $3.5M | $4.5M | $17.1M | $25.8M | $32.7M | $32.9M | $24.9M | $25.1M | $25.3M |
| Cash & short-term investments | $88.0M | $8.6M | $14.2M | $7.3M | $33.5M | $97.0M | $55.1M | $4.4M | $15.9M | $8.1M |
| Net debt | −$85.8M | −$5.1M | −$9.8M | $9.7M | −$7.8M | −$64.3M | −$22.2M | $20.5M | $9.1M | $17.2M |
| Debt / equity | 0.03 | 0.24 | 0.21 | 1.11 | 0.41 | 0.30 | 0.58 | 10.10 | 1.55 | 2.83 |
| Debt / assets | 0.02 | 0.15 | 0.16 | 0.41 | 0.26 | 0.22 | 0.35 | 0.81 | 0.58 | 0.70 |
| Current ratio | 7.85 | 1.59 | 4.08 | 1.22 | 1.48 | 15.74 | 11.79 | 1.39 | 8.00 | 4.26 |
| Quick ratio | 7.85 | 1.59 | 4.08 | 0.24 | 1.35 | 15.74 | 11.64 | 1.39 | 8.00 | 4.25 |
| Interest coverage | -663.0 | -87.7 | -96.7 | -353.1 | -21.0 | -12.7 | -5.7 | -8.3 | -7.4 | -7.4 |
| Working capital | $80.5M | $3.6M | $11.8M | $4.7M | $14.6M | $98.0M | $56.5M | $1.4M | $14.2M | $6.6M |
| Invested capital | −$128,000 | $9.8M | $11.6M | $25.1M | $55.7M | $44.3M | $34.4M | $22.9M | $25.3M | $26.1M |
| Tangible asset value | $83.9M | $8.0M | $16.0M | $10.0M | $58.6M | $107.6M | $55.5M | $1.1M | $14.5M | $7.1M |
| Net current asset value | $78.8M | $1.4M | $8.3M | $433,000 | $9.1M | $66.2M | $24.2M | −$23.3M | −$10.6M | −$18.5M |
| Graham net-net per share | $0.73 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $500,000 | — | — | $21.6M | — | $0 | $0 |
| Share buybacks (net) | — | $0 | $7,000 | $39,000 | $0 | — | $40.8M | $159,000 | $125,000 | $0 |
| Capex / revenue | 578.0% | 4.0% | 93.3% | 11,476.0% | 389.1% | 217.7% | 70.5% | 49.1% | 243.0% | 404.3% |
| Capex / depreciation | 0.56 | 0.01 | 0.17 | 4.16 | 1.93 | 2.14 | 0.51 | 0.57 | 0.63 | 0.95 |
| Stock-based compensation / revenue | 1,373.0% | 382.5% | 905.8% | 8,782.0% | 232.3% | 66.9% | 23.7% | 11.9% | 173.4% | 256.3% |
| R&D / revenue | 19,643.0% | 2,078.0% | 2,304.4% | 20,654.0% | 521.6% | 421.3% | 218.1% | 271.3% | 897.7% | 1,044.9% |
| SG&A / revenue | 10,595.0% | 2,672.5% | 5,188.4% | 38,032.0% | 1,154.7% | 923.2% | 693.8% | 611.1% | 2,406.5% | 2,677.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 2,206.4 | 373.2 | 743.8 | 23,009.6 | 1,126.2 | 858.2 | 637.4 | 15.6 | 102.8 | 361.8 |
| Days of inventory on hand | — | — | — | 4,123.6 | 189.0 | 103.0 | 207.2 | — | — | 0.7 |
| Days payables outstanding | 1,171.4 | — | 322.2 | 1,008.7 | 313.8 | 500.9 | 716.5 | — | 15.8 | 14.2 |
| Cash conversion cycle (days) | 1,035.1 | — | 421.6 | 26,124.5 | 1,001.5 | 460.3 | 128.1 | — | 87.3 | 348.3 |
| Receivables turnover | 0.17 | 0.98 | 0.49 | 0.02 | 0.32 | 0.43 | 0.57 | 23.47 | 3.55 | 1.01 |
| Payables turnover | 0.31 | 0.00 | 1.13 | 0.36 | 1.16 | 0.73 | 0.51 | 0.00 | 23.11 | 25.75 |
| Inventory turnover | — | — | — | 0.09 | 1.93 | 3.54 | 1.76 | 0.00 | — | 541.33 |
| Asset turnover | 0.00 | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | 0.03 | 0.05 | 0.01 | 0.01 |
| Average receivables | $604,500 | $409,000 | $458,500 | $3.2M | $5.8M | $5.6M | $2.9M | $86,000 | $125,000 | $390,500 |
| Average payables | $3.3M | $1.3M | $1.1M | $3.1M | $3.3M | $2.0M | $1.4M | $895,500 | $561,000 | $504,500 |
| Average inventory | — | — | — | $12.5M | $2.0M | $412,500 | $399,000 | $0 | $13,000 | $24,000 |
| Intangibles / total assets | 1.8% | 29.5% | 18.7% | 13.1% | 4.9% | 0.6% | 1.2% | 4.5% | 3.8% | 5.1% |
Computed from IBIO's annual financial statements (latest annual report filed August 28, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IBIO valuation and financial ratios
iBio earned a return on equity of −65.7% in fiscal 2026. It ended the year with $2.2 million of debt and $88.0 million in cash and short-term investments, a net cash position of $85.8 million.
See the IBIO income statement, the IBIO chart for price history, or the IBIO stock overview for the latest quote and news.
IBIO key metrics FAQ
What is iBio's return on equity?
iBio's return on equity (ROE) was −65.7% in fiscal 2026: net income of -$33.0 million on average shareholders' equity of $50.3 million.
How much debt does iBio have?
iBio had total debt of $2.2 million at the end of fiscal 2026, a debt-to-equity ratio of 0.03 and more cash than debt.
What is iBio's free cash flow yield?
iBio generated -$23.8 million of free cash flow in fiscal 2026, a free cash flow yield of −13.1% on its market value at year-end ($182.1 million).
What is iBio's current ratio?
iBio's current ratio was 7.85 at the end of fiscal 2026: current assets were 7.85 times current liabilities.